This is a summary of the European public assessment report (EPAR) for Mirvaso. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mirvaso. For practical information about using Mirvaso, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
Therapeutic Area (MeSH)
N/AATC Code
D11AX21
ATC Item
brimonidine
Pharmacotherapeutic Group
Other dermatological preparations
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| brimonidine tartrate | N/A | 溴莫尼定 |
EMA Name
Mirvaso
Medicine Name
Mirvaso
Aliases
N/ANo risk management plan link.
